Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1967 4
1968 3
1969 6
1970 5
1971 12
1972 9
1973 1
1974 5
1975 10
1976 7
1977 4
1978 8
1979 6
1980 1
1981 8
1982 4
1983 5
1984 4
1985 6
1986 6
1987 5
1988 4
1989 6
1990 3
1991 8
1992 5
1993 3
1994 8
1995 4
1996 8
1997 10
1998 9
1999 7
2000 16
2001 15
2002 10
2003 11
2004 16
2005 21
2006 16
2007 17
2008 21
2009 9
2010 18
2011 15
2012 27
2013 29
2014 23
2015 28
2016 28
2017 18
2018 28
2019 24
2020 29
2021 20
2022 20
Text availability
Article attribute
Article type
Publication date

Search Results

612 results
Results by year
Filters applied: . Clear all
Page 1
Betahistine for symptoms of vertigo.
Murdin L, Hussain K, Schilder AG. Murdin L, et al. Cochrane Database Syst Rev. 2016 Jun 21;2016(6):CD010696. doi: 10.1002/14651858.CD010696.pub2. Cochrane Database Syst Rev. 2016. PMID: 27327415 Free PMC article. Review.
This review examines whether betahistine is more effective than a placebo at treating symptoms of vertigo from different causes. OBJECTIVES: To assess the effects of betahistine in patients with symptoms of vertigo from different causes. ...
This review examines whether betahistine is more effective than a placebo at treating symptoms of vertigo from different causes. OBJE …
Use of betahistine in the treatment of peripheral vertigo.
Ramos Alcocer R, Ledezma Rodríguez JG, Navas Romero A, Cardenas Nuñez JL, Rodríguez Montoya V, Deschamps JJ, Liviac Ticse JA. Ramos Alcocer R, et al. Acta Otolaryngol. 2015;135(12):1205-11. doi: 10.3109/00016489.2015.1072873. Epub 2015 Aug 6. Acta Otolaryngol. 2015. PMID: 26245698 Review.
The review also presents an update on the mechanisms of action, pharmacodynamics, and pharmacokinetics of betahistine. RESULTS: Efficacy and safety of betahistine has been demonstrated in numerous clinical trials. The precise mechanism of action of betahistine
The review also presents an update on the mechanisms of action, pharmacodynamics, and pharmacokinetics of betahistine. RESULTS: Effic …
Efficacy and Safety of a Fixed Combination of Cinnarizine 20 mg and Dimenhydrinate 40 mg vs Betahistine Dihydrochloride 16 mg in Patients with Peripheral Vestibular Vertigo: A Prospective, Multinational, Multicenter, Double-Blind, Randomized, Non-inferiority Clinical Trial.
Scholtz AW, Hahn A, Stefflova B, Medzhidieva D, Ryazantsev SV, Paschinin A, Kunelskaya N, Schumacher K, Weisshaar G. Scholtz AW, et al. Clin Drug Investig. 2019 Nov;39(11):1045-1056. doi: 10.1007/s40261-019-00858-6. Clin Drug Investig. 2019. PMID: 31571128 Free PMC article. Clinical Trial.
The objective of the present study was to evaluate whether the fixed combination of cinnarizine and dimenhydrinate (Arlevert()) is non-inferior and thus a potentially useful alternative to betahistine dihydrochloride in the treatment of patients suffering from perip …
The objective of the present study was to evaluate whether the fixed combination of cinnarizine and dimenhydrinate (Arlevert()) is non-infer …
Menière's disease.
Wright T. Wright T. BMJ Clin Evid. 2015 Nov 5;2015:0505. BMJ Clin Evid. 2015. PMID: 26545070 Free PMC article. Review.
METHODS AND OUTCOMES: We conducted a systematic overview, aiming to answer the following clinical questions: What are the effects of combination treatment (betahistine plus thiazide diuretic) to prevent attacks and delay disease progression of Meniere's disease? ...CONCLUS …
METHODS AND OUTCOMES: We conducted a systematic overview, aiming to answer the following clinical questions: What are the effects of combina …
Efficacy and safety of betahistine treatment in patients with Meniere's disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial).
Adrion C, Fischer CS, Wagner J, Gürkov R, Mansmann U, Strupp M; BEMED Study Group. Adrion C, et al. BMJ. 2016 Jan 21;352:h6816. doi: 10.1136/bmj.h6816. BMJ. 2016. PMID: 26797774 Free PMC article. Clinical Trial.
STUDY QUESTION: What is the long term efficacy of betahistine dihydrochloride on the incidence of vertigo attacks in patients with Meniere's disease, compared with placebo? ...Adults aged 21-80 years (mean age 56 years) with definite unilateral or bilateral Meniere' …
STUDY QUESTION: What is the long term efficacy of betahistine dihydrochloride on the incidence of vertigo attacks in patients …
Effects of vestibular rehabilitation, with or without betahistine, on managing residual dizziness after successful repositioning manoeuvres in patients with benign paroxysmal positional vertigo: a protocol for a randomised controlled trial.
Wu P, Cao W, Hu Y, Li H. Wu P, et al. BMJ Open. 2019 Jun 18;9(6):e026711. doi: 10.1136/bmjopen-2018-026711. BMJ Open. 2019. PMID: 31217316 Free PMC article.
This study aims to investigate the efficacy of VR, compared with betahistine or VR plus betahistine treatment, in the treatment of patients experiencing RD after successful CRP. ...Participants will be randomised into one of three groups to receive VR, betahistin
This study aims to investigate the efficacy of VR, compared with betahistine or VR plus betahistine treatment, in the treatmen …
[Betahistine in vestibular disorders: current concepts and perspectives].
Zamergrad MV, Kunelskaya NL, Guseva AL, Amelin AV, Lilenko SV, Samartcev IN, Zaytseva OV, Melnikov OA, Voronov VA, Lyapin AV. Zamergrad MV, et al. Vestn Otorinolaringol. 2021;86(2):73-81. doi: 10.17116/otorino20218602173. Vestn Otorinolaringol. 2021. PMID: 33929156 Review. Russian.
Betahistine is a weak agonist for histamine H1 receptors and strong antagonist for histamine H3 receptors. ...In vestibular neuritis betahistine stimulates central compensation during vestibular rehabilitation. ...
Betahistine is a weak agonist for histamine H1 receptors and strong antagonist for histamine H3 receptors. ...In vestibular neuritis
Betahistine in Ménière's Disease or Syndrome: A Systematic Review.
Van Esch B, van der Zaag-Loonen H, Bruintjes T, van Benthem PP. Van Esch B, et al. Audiol Neurootol. 2022;27(1):1-33. doi: 10.1159/000515821. Epub 2021 Jul 7. Audiol Neurootol. 2022. PMID: 34233329 Free article.
BACKGROUND: Meniere's disease is characterized by recurrent episodes of vertigo, hearing loss, and tinnitus, often with a feeling of fullness in the ear. Although betahistine is thought to be specifically effective for Meniere's disease, no evidence for a benefit from the …
BACKGROUND: Meniere's disease is characterized by recurrent episodes of vertigo, hearing loss, and tinnitus, often with a feeling of fullnes …
612 results